ThermiAesthetics gets $9M in debt; Quanta gets CE mark for portable hemodialysis;

@FierceMedDev: Graphene 'flying carpet' strips deliver two #cancer drugs, each to a different cell target. Article | Follow @FierceMedDev

@EmilyWFierce: Cancer Genetics gets nod to offer cancer testing in California. Story | Follow @EmilyWFierce

> ThermiAesthetics has secured $9 million in debt from Cypress Growth Capital and Silicon Valley Bank to get to market and expand the indications for its ThermiRF Temperature Controlled Radio Frequency Generator System, which is FDA-approved for dermatological and general surgical procedures, for electrocoagulation and hemostasis and to create lesions in nervous tissue. It will also use it further develop and launch in the U.S. its ThermiVa system for vaginal laxity. Release

> The Wall Street Journal takes a closer look at passive, depression tracking app company, which raised $20 million earlier this week. Story (sub. req.)

> Quanta Fluid Solutions got a CE mark for its portable, cartridge-based hemodialysis system and expanded a recent investment to £29 million. The round was led by new investor ALIAD, the venture capital investment vehicle of Air Liquide, and included participation by additional new investors Seventure Partners and Kuwait Life Sciences Company, as well as existing investors Wellington Partners, Seroba Kernel, NBGI Ventures, b-to-v Partners and IMI. Release

> A U.K professional rugby team is testing the xPatch from Seattle-based X2 Biostems, which measures the impact of head collisions by tracking rotation, tilt, movement and speed. Story

Biotech News

@FierceBiotech: Aveo guts its R&D operation, cutting two-thirds of its payroll. Item | Follow @FierceBiotech

@JohnCFierce: Eyeing an IPO, Genkyotex banks a $21M round for PhII study -- NOX inhibition. Story | Follow @JohnCFierce

@DamianFierce: Another roughly $65M in biotech VC announced today, making for a three-day total nearing $700M. | Follow @DamianFierce

> Alkermes sees PhII promise for schizophrenia drug that doesn't pack on pounds. Story

> Pfizer, NEA orphan drug project launches its first biotech on PhII/III threshold. Report

> Zafgen's promising obesity drug comes through in another midstage trial. More

> Blend banks $21M for its nano-assisted cancer drugs. Article

Pharma News

@FiercePharma: Whistle-blowing Bayer sales rep wins again in wrongful termination suit. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bayer drafts 'Community' star to launch cult-favorite hangover cure in U.S. More | Follow @CarlyHFierce

> New study clears Merck's blockbuster Gardasil of MS risk. News

> Roche and GSK set for sales growth in this year's fast-spreading flu epidemic. Report

Drug Delivery News

> Palo Alto pain management startup Carbylan vies for $86M IPO. Article

> Blend Therapeutics receives $21M in Series B round. Item

> Australia's EnGeneIC receives $10M in Series B round for studies of anticancer delivery tech. News

> Graphene 'flying carpet' strips deliver two cancer drugs, each to a different cell target. Report

> NeuroDerm's subcutaneously delivered alternative to oral levodopa shows promise in Parkinson's trial. More

Diagnostics News

> HTG Molecular Diagnostics mulls $60M IPO for next-gen profiling technology. Report

> Illumina blazes into 2015 with plans for new California campus. News

> Molecular Dx maker CombiMatrix wins a battle in insurance fraud lawsuit. Article

> Cancer Genetics gets nod to offer cancer testing in California. More

> Israel's Itamar looks to China, Canada and beyond for growth. Story

Pharma Marketing News

> Do rival DTC campaigns help your own brand? Yes, a study shows--up to a point. Report

> FDA's marketing police wrote only 10 tickets in 2014. Story

> Whistle-blowing Bayer sales rep wins again in wrongful termination suit. More

> Pfizer complains, advertising watchdog acts against Novartis Theraflu promo. Article

> Bayer drafts 'Community' star to launch cult-favorite hangover cure in U.S. News

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.